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Tight glycemic control in the ICU has been shown to
reduce mortality in some but not all prospective
randomized control trials. Confounding the
interpretation of these studies are differences in how
the control was achieved and underlying incidence of
hypoglycemia, which can be expected to be affected
by the introduction of continuous glucose monitoring
(CGM). In this issue of Critical Care, a consensus panel
provides a list of the research priorities they believe
are needed for CGM to become routine practice in
the ICU. We reflect on these recommendations and
consider the implications for using CGM today.of the effect of different treatment algorithms on thisContinuous glucose control in the ICU: report of a 2013
Round Table meeting, published in this issue of Critical
Care [1], summarizes the discussion and recommenda-
tions of a round table meeting on the management of
blood glucose levels in the ICU. The self-selected panel
of authors recommends eight areas where it believes re-
search is needed, beginning with head-to-head compari-
sons of different continuous glucose monitoring (CGM)
devices and ending with randomized controlled studies
validating closed-loop insulin delivery.
Appropriately, the recommendations focus on what is
needed to advance CGM into the ICU and do not ad-
dress whether tight glycemic control is beneficial or
what the appropriate target range should be. Nonethe-
less, the answers to these questions will impact the im-
portance of the recommendations. Of the prospective
randomized controlled studies performed to date, many
have failed to show a clinical benefit to tight glycemic
control (TGC) - including our own study in children less
than 3 years of age following cardiac surgery [2]. Our* Correspondence: michael.agus@childrens.harvard.edu
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2014current study assessing the possible benefit of TGC in
hyperglycemic critically ill children with cardiovascular
and/or respiratory failure (NCT01565941) seeks to an-
swer the question whether control in the target range 80
to 110 mg/dL results in better outcomes than control in
the 150 to 180 mg/dL target range. Clearly, if the 80 to
110 mg/dL range proves beneficial, the need to intro-
duce CGM into the ICU will be paramount as this target
range is difficult to achieve without increasing the inci-
dence of hypoglycemia. This may be less important if
the 150 to 180 mg/dL range is shown to be equally ef-
fective. It is possible that TGC with CGM will reduce
glucose variability irrespective of the target range, and
the panel’s recommendations appropriately call for study
metric. However, it should be noted that the evidence
the authors cite supporting the importance of glycemic
variability [3] is based on retrospective analysis, which
cannot be used to infer causality.
Still, the question remains as to how best to manage
glucose levels in critically ill patients today. Putting aside
whether control in a low target range is better than in a
higher range, or whether a reduction in glucose variabil-
ity per se improves clinical outcomes, there are low and
high glucose levels that would be treated today in virtu-
ally every ICU. Every effort needs to be made to avoid
these ends of the spectrum. To this end, one might ask
whether CGM devices should be used in the ICU now.
One can correctly infer from the recommendations that
there have been no head-to-head comparisons of differ-
ent CGM devices, and that the trends reported have also
not been validated. Likewise, investigators who have
established insulin protocols at their institutions might
ask whether the protocols need to be re-evaluated given
the marked differences in insulin recommendations
noted by Wilson and colleagues [4] in work highlighted
by the consensus panel. Our own review of TGC proto-
cols concurs with that of Wilson and colleagues [4] in
that we also noted substantive differences among theal Ltd. The licensee has exclusive rights to distribute this article, in any medium, for
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ally all the protocols could be expected to achieve and
maintain their desired target glucose ranges and each
could be reasonably expected to benefit from the use of
CGM devices.
Conclusion
We emphasize again that the benefit of TGC in the ICU
has not yet been established, and argue that equipoise
for this and other questions related to TGC in the ICU
be maintained. We agree more studies of CGM in the
ICU are needed, but encourage investigators to consider
whether the existing CGM devices might reduce the ex-
treme high or low glucose values that occur during rou-
tine care. We conclude with a statement put forth by Dr
Kavanagh [6] in his editorial accompanying our study of
TGC in young children [2] in which he states: "Perhaps
the most important question from a decade of studying
glucose control in the ICU is how influential practice
guidelines advocating tight glucose control were devel-
oped yet turned out to be harmful … guideline writers,
reflecting on the experience, must accept that there are
multiple sources of clinical knowledge. Clinicians in turn
should use guidelines wisely, recognizing that no single
source of knowledge is sufficient to guide clinical deci-
sions." We agree and would point out there is an inher-
ent danger in consensus opinion replacing clinical
evidence. At one point in history the consensus was that
the earth was flat.
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